Home › Research › Topics › pet
pet
1,164 studies tagged pet, dated 1983-08-01 to 2026-11-01. Bibliography: BibTeX (.bib) · RIS (.ris)
Newest in this topic
- Large-scale head-to-head comparison of on- and off-target profiles of [18F]Tauvid and [18F]MK6240 tau-PET in aging and Alzheimer’s disease 2026-11-01
- Detection of tau spatial extent using MK6240 and flortaucipir PET 2026-10-28
- Soluble amyloid composition links proximal APP processing, fibrillar burden and the p-tau181 response 2026-10-22
Studies
1,164 studies carry this tag.
Date range
1983 to 2026
Top journals
- Neurology 88
- Alzheimer's & dementia : the journal of the Alzheimer's Association 58
- Brain : a journal of neurology 52
- Journal of nuclear medicine : official publication, Society of Nuclear Medicine 52
- Alzheimer's research & therapy 34
337 journals in all.
Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.
-
Females had higher rates of positive amyloid PET visual reads (63% vs. 59%, P < 0.001) and higher Centiloids (CLs; median 48.7 vs. 36.8, p < 0.001).
-
Penyakit Alzheimer adalah jenis demensia akibat kerusakan pada neuron otak yang memengaruhi memori, bahasa, dan berpikir.
-
28/100
Alzheimer's disease is a neurodegenerative disorder affecting millions globally, with early detection being critical for effective management.
-
Alzheimers disease (AD) represents the most prevalent form of dementia, affecting millions worldwide and posing significant public health challenges.
-
Research interest in the application of electroencephalogram (EEG) as a non-invasive diagnostic tool for the automated detection of neurodegenerative diseases is growing.
-
DNA methylation is a critical epigenetic mechanism involved in numerous physiological processes.
-
Machine learning (ML) on structural MRI data shows high potential for classifying Alzheimer's disease (AD) progression, but the specific contribution of brain regions, demographics, and proteinopathy remains unclear.
-
Alzheimer's disease (AD) is characterized by deficits in cognition, behavior, and intellectual functioning, and Mild Cognitive Impairment (MCI) refers to individuals whose cognitive impairment deviates from what is expected for their age but does not significantly interfere with daily activities.
-
31/100
Alzheimer’s disease (AD) is a progressive neurodegenerative condition that affects the elderly population.
-
18 F-Flortaucipir, as a classical Tau protein visualizer, has been widely used in the diagnosis of neurodegenerative diseases, especially Alzheimer disease.
-
Patients with dementia face increased risks after general anesthesia.
-
Amyloid-PET demonstrated high sensitivity (100% in year 1, 94.67% in year 4) and a high negative predictive value (100% in year 1, 88.24% in year 4).
-
Data from 17 107 individuals (321 Asian, 635 Black, 829 Hispanic, and 15 322 White) with MCI or dementia and amyloid PET were analyzed between April 2020 and January 2022.
-
AD patients had significantly higher AD-RAI (0.91 ± 0.25) and more pronounced hippocampal atrophy (0.36 ± 0.09) compared to MCI and HC (P 0.9 for distinguishing BPSD from non-BPSD patients.
-
Alzheimer's dementia (AD) is a degenerative brain disease characterized by a decline in cognitive function and memory.
-
The study highlights the potential of integrating 18 F-FDG-PET with CSF biomarkers to improve the diagnosis, prognosis, and monitoring of AD, emphasizing the complexity and regional specificity of biomarker interactions in neurodegeneration.
-
The advent of disease-modifying therapies for neurodegenerative diseases may result in a growing demand for nuclear neuroimaging procedures presenting opportunities but also challenges to the nuclear medicine community.
-
The GBT model achieved the best AUC-ROC scores of 0.809-0.833 across 1- to 5-year prediction windows.
-
In this paper, we propose a deep super-resolution generative adversarial network (DSR-GAN) combined with a convolutional neural network (CNN) model designed to classify four stages of Alzheimer's disease (AD): Mild Dementia (MD), Moderate Dementia (MOD), Non-Demented (ND), and Very Mild Dementia (VMD).
-
We evaluated 62 Automated speech analysis demonstrated high accuracy in differentiating FTD subtypes and provided insights into the neural basis of language impairments.
-
Alzheimer's disease (AD) is a memory and cognitive function neurodegenerative disease.
-
A progressive neurological disease, Alzheimer's disease (AD) is identified by cognitive decline and memory loss.
-
Greater intra-group heterogeneity in ATN abnormality patterns was observed in more severe clinical stages of AD.
-
Dementia is a growing global health concern that significantly impacts the quality of life for millions of individuals and imposes substantial burdens on healthcare systems.
-
This approach predicts clinical progression (2-year Clinical Dementia Rating Sum of Boxes change > 1) with an area under the curve of 0.836.
-
Early and accurate diagnosis of Alzheimer's disease (AD) will be key for effective personalized treatment plans ( Cummings, 2023).
-
This paper introduces a novel convolutional neural network model with an attention mechanism to advance Alzheimer disease (AD) classification using Magnetic Resonance Imaging (MRI).
-
MobileNet achieved the highest overall performance, with an accuracy of 99.44%.
-
weighted MRI can assess macro-structural brain atrophy, diffusion tensor imaging (DTI) unveils these hidden microstructural alterations.
-
BPSD severity was independent from cognitive impairment, vascular impairment, white matter lesions and ApoE status.
-
The subdivisions exhibit different pathways, terminations, and structural characteristics.
-
Nine phase 3 RCT cohorts from 8 eligible studies were identified, analyzing data from 6,315 patients.
-
< 0.001). Shape features demonstrated the highest predictive accuracy for conversion, with areas under the curve of 0.891 at baseline and 0.898 at 2 years.
-
Comorbid cardiovascular and metabolic risk factors (CVM) differentially impact brain structure and increase dementia risk, but their specific magnetic resonance imaging signatures (MRI) remain poorly characterized.
-
43/100
The density of brain amyloid-beta neuritic plaque accumulation, a marker of Alzheimer's disease (AD), can be visualized and quantified using amyloid-positron emission tomography (PET).
-
Mutations in the Integral membrane protein 2B (ITM2B) gene are linked to the development of familial British and Danish dementias, two relatively early-onset dementia disorders known also to be associated with Tau neurofibrillary tangles (NFTs).
-
53/100
Amyloid burden is an important prognostic marker in a clinically heterogeneous cohort.
-
The FCAAS-4 achieved a mean area under the receiver operating characteristic curve (AUC-ROC) of 0.74 (95% confidence interval: 0.71-0.77) and a Harrell generalized c-index of 0.72 (0.70-0.75).
-
The deep-learning network was capable of learning the task of delineating pathologic and normal findings within minutes on a standard PC and performing the classification task with 100% accuracy in less than 1 millisecond per case.
-
All six CTE stage III cases had Braak NFT stage III but no neuritic plaques.
-
Alzheimer’s disease (AD) is a neurodegenerative disorder that affects millions of people worldwide.
-
Alzheimer’s disease (AD) is the most common cause of dementia, emphasizing the critical need for the development of biomarkers that facilitate accurate and objective assessment of disease progression for early detection and intervention to delay its onset.
-
This study classified preclinical Alzheimer's disease (AD) using cognitive screening, neighborhood deprivation via the area deprivation index (ADI), and sociodemographic and genetic risk factors.
-
41/100
IRMA can be used to learn and disregard center-specific information in features extracted from brain $$^{18}$$ 18 F-FDG PET scans, while retaining disease-specific information.
-
Alzheimer's Disease (AD) is a progressive condition of a neurological brain disorder recognized by symptoms such as dementia, memory loss, alterations in behaviour, and impaired reasoning abilities.
-
BackgroundA novel neuroimaging signature of regional cortical thickness on brain MRI recently showed high potential for Alzheimer's disease and related dementias (ADRD) risk stratification in the community.
-
Alzheimer's Disease (AD) is a particular form of dementiacharacterized by a steady decline in brain function and cognitive abilities, leading to memory loss, disorientation, and trouble doing daily tasks.
-
The aAD patients showed significantly higher tau accumulation, relative hypoperfusion and grey matter density loss in the temporal lobes compared to PCA and lvPPA patients.
-
After controlling for the level of cognitive impairment, we found a double dissociation between AD clinical phenotype and localization/magnitude of atrophy, characterized by predominant neocortical involvement in EOAD and more focal anterior medial temporal involvement in LOAD.
-
Interquartile range differences in amyloid beta 42/40, percent phosphorylated tau 217 (%p-tau217), and Amyloid Probability Score 2 were associated with 1.29 (P = 0.09), 1.38 (P < 0.001), and 1.20 (P = 0.05) increases, respectively, in the hazard of progression from A- to A+ and 0.27 (P = 0.16), 0.50 (P = 0.007), and 0.28 (P = 0.15) Centiloid/year increases, respectively, in annual rate of amyloid PET change.
From across this tag
10 of the 1,160 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Impaired default network functional connectivity in autosomal dominant Alzheimer disease
- PET-guided Assessment of Amyloid Clearance and Outcomes in a Real-World Cohort of Patients with Alzheimer Disease undergoing Anti-Amyloid Therapy
- Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes
- Novel white matter tract integrity metrics sensitive to Alzheimer disease progression
- The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods
- Soluble amyloid composition links proximal APP processing, fibrillar burden and the p-tau181 response
- Entorhinal Tau Pathology, Episodic Memory Decline, and Neurodegeneration in Aging
- The amnestic syndrome of hippocampal type in Alzheimer's disease: an MRI study
- Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: Recommendations of an expert panel
- Subtypes of progressive aphasia: application of the International Consensus Criteria and validation using β-amyloid imaging